Clinical Trial: The Propel Study in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

Generalized myasthenia gravis (gMG) affects the muscles that people can control. The muscles in our bodies need signals from our nerves to work properly. When these signals are interrupted or lost, muscles feel weak and get tired easily.

Symptoms of gMG can include muscle weakness, and trouble chewing, talking, or swallowing. In more than half of people who develop myasthenia gravis, their first signs and symptoms involve eye problems such as drooping of one or both eyelids, or double vision.

Symptoms tend to progress over time, usually reaching their worst within a few years after the onset of the disease. Though this disease can affect people of any age, it’s more common in women younger than 40 and in men older than 60.

The PROPEL Study will test an investigational treatment for generalized myasthenia gravis (gMG) called IMVT-1402 to see if it may help the body’s muscles get the signals they need to work properly. In this clinical trial, researchers hope to learn how IMVT-1402 works in the body and if it is safe and effective for people with mild to severe gMG.

Individuals may qualify for the study if they:

• Are 18 to 80 years of age
• Have been diagnosed with mild to severe generalized myasthenia gravis (gMG)
• Are being treated or have been treated with one or more medication(s) for gMG
• Meet additional study criteria

Reimbursement for reasonable, out-of-pocket expenses for travel and accommodations may be available to qualified individuals.

To learn more about the PROPEL Study, click here to watch a short video.

If you’re interested in participating in a clinical trial of a potential therapy for generalized myasthenia gravis, ask your doctor or visit Propel.researchstudytrial.com to learn more about the PROPEL Study.

.